scholarly journals Characterization of a plant-produced recombinant human secretory IgA with broad neutralizing activity against HIV

mAbs ◽  
2014 ◽  
Vol 6 (6) ◽  
pp. 1585-1597 ◽  
Author(s):  
Matthew Paul ◽  
Rajko Reljic ◽  
Katja Klein ◽  
Pascal MW Drake ◽  
Craig van Dolleweerd ◽  
...  
1988 ◽  
Vol 101 (3) ◽  
pp. 565-575 ◽  
Author(s):  
N. P Leschinskaya ◽  
E. E Pokrovskaya ◽  
E. A Kantorovitch ◽  
S.K Grigorjeva ◽  
YA. S Shvartsman

SUMMARYExamination of sera from 184 children aged between 0 and 12 years and 161 adults revealed a close correlation between age and the level of humoral anti-RS virus immunity. Secretory IgG antibodies were found in children in their first months of life. Evidence for their release into secretions from the serum was obtained. This might explain the positive correlation between serum antibody levels in women recently confined with the morbidity due to RS virus in children during their first months of life. Secretory IgA antibodies were found from 4 months untill old age. The secretions of children and adults contained virus-neutralizing activity which was non-immunoglobulin in nature, as well as antibodies. However, in contrast to secretory antibody this material did not prevent development of severe RS virus infections.


2005 ◽  
Vol 79 (21) ◽  
pp. 13199-13208 ◽  
Author(s):  
Zhen-Yong Keck ◽  
Ta-Kai Li ◽  
Jinming Xia ◽  
Birke Bartosch ◽  
François-Loïc Cosset ◽  
...  

ABSTRACT Hepatitis C (HCV) E2 glycoprotein is involved in virus attachment and entry, and its structural organization is largely unknown. Characterization of a panel of human monoclonal antibodies (HMAbs) to HCV by competition studies has led to an immunogenic organization model of E2 with three domains designated A, B, and C and epitopes in each domain having similar structural and functional properties. Domain A contains nonneutralizing epitopes, and domains B and C contain neutralizing epitopes. The isolation and characterization of three new HMAbs within domain A for a total of six provide support for this model. All six domain A HMAbs do not neutralize HCV retroviral pseudotype particle (HCVpp) infection on Huh-7 cells, and all six HMAbs have similar binding affinity and maximum binding, B max, a relative indicator of epitope density, as other neutralizing HMAbs, suggesting that neutralization is epitope specific and not by binding to any surface epitope. The dose-dependent neutralizing activity of CBH-7, an HMAb to a domain C epitope in spatial proximity to domain A, and of CBH-5, a domain B HMAb to a more distant epitope, were tested in the presence and absence of each domain A HMAb. No enhancement or reduction in CBH-7 or CBH-5 neutralizing activity was observed, indicating that the potential induction of nonneutralizing antibodies should not be a central issue for HCV vaccine design. To assess whether domain A is involved in the structural changes as part of a pH-dependent virus envelope fusion process, changes in antibody binding patterns to normal pH and acid pH-treated HCVpp were measured. Antibody binding affinity of HMAbs to HCVpp was not affected by low pH. However, the B max values for low-pH-treated HCVpp with antibodies to domain A increased 46%, for domain C (CBH-7) they increased 23%, and for domain B (CBH-5) there was a decrease of 12%. Collectively, the organization and function of HCV E2 antigenic domains are roughly analogous to the large envelope glycoprotein E organizational structure for other flaviviruses with three distinct structural and functional domains.


2019 ◽  
Author(s):  
Chao Wang ◽  
Xianpu Ni ◽  
Ying Liu ◽  
Zheng Jin ◽  
Huanzhang Xia

Tumor necrosis factor alpha (TNFα) is now regarding as a key role in the pathogenesis of immune-mediated disease such as Rheumatoid arthritis (RA), Crohn's Disease, Psoriatic arthritis and Plaque Psoriasis. HERE we have successfully developed an anti-hTNFα monoclonal rabbit antibody(HZ3M) with high binding and neutralizing activity based on RabMAbs platform. Rabbit hybridomas, immunized subcutanrously with 0.4 mg human TNFα, were generated from the rabbit splenocytes and a total of 142 hybridoma clones with specific binding to human TNFa were obtained. The anti-TNFa RabMAbs showed better neutralizing activity and higher antigen binding affinity compared to Humira and Remicade, the elimination phase half-life 58.2h respectively. In vivo efficay studies, normal mice or human TNF-alpha transgenic mice were injected with 1.0 mg/kg Humira (positive control), HZ3M at 0.33?1.0 or 3.0 mg/kg, or solvent (negative control), showed that HZ3M is able to bind and neutralize hTNFα in transgenic and normal mice as well as normal rabbits.Clearly dose-dependent response can be determined. Compared to marketed anti-TNFa drug Humira, the efficacy of HZ3M is seems to show significant longer holding time.Our observations indicate that the HZ3M derived from RabMAb preclinical safety study, and might have a therapeutic role in RA treatment.


2016 ◽  
Vol 226 ◽  
pp. 85-92 ◽  
Author(s):  
Qinye Song ◽  
Suzanne Stone ◽  
Donna Drebes ◽  
Laura L. Greiner ◽  
Cheryl M.T. Dvorak ◽  
...  

1997 ◽  
Vol 27 (4) ◽  
pp. 417-423 ◽  
Author(s):  
R. Tarazona ◽  
N.C. Lally ◽  
M. Dominguez-Carmona ◽  
D.A. Blewett

Sign in / Sign up

Export Citation Format

Share Document